Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
1don MSN
CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly earnings results, demand for Wegovy, drug pipeline outlook, Cagrisema ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...
9don MSN
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Hosted on MSN1d
Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower Growth Outlook To Chase Obesity Drug BoomNYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback